Search Results 1771-1780 of 17066 for monoclonal antibody
... antibodies). New onset or signs and symptoms of any form of ... Prior exposure to any anti-IgE antibody therapy other than omalizumab and ligelizumab.
Prior exposure to any anti-PD-1 or anti-PD-L1 antibody; Any concurrent chemotherapy, immunotherapy, biologic or hormonal therapy for cancer treatment. Prior ...
... antibody and/or small molecule treatment is allowed, except for PARP inhibitors). Life expectancy >6 months; ECOG performance status 0 or 1. (Form is ...
Diagnosis of smoldering MM, Waldenström's macroglobulinemia, POEMS (polyneuropathy, organomegaly, endocrinopathy, monoclonal gammopathy, and skin changes) ...
Patients with a history of prior treatment with anti-PD-1, anti-PD-L1, anti-PDL2, anti- CTLA-4 antibodies, other checkpoint inhibitors. Other protocol ...
Must have detectable (above the lower limit of detection) serum celiac-related antibodies. Must have human leukocyte antigen DQ (HLA-DQ) typing consistent ...
Positive patient anti-donor HLA antibody, which is deemed clinically significant. Prior allogeneic marrow or stem cell transplantation. Prior solid organ ...
Diagnosed with celiac disease based on positive serology (eg, tissue transglutaminase IgA antibody and/or deamidated gliadin peptide IgG) and intestinal ...
... antibodies and the factors that may determine disease progression and treatment response. Safety/Efficacy of MEDI-551 in Combination With Immunomodulating ...
Immunotoxins, such as inotuzumab ozogamicin, are antibodies linked to a toxic substance and may help find cancer cells that express CD22 and kill them without ...
Mayo Clinic does not endorse companies or products. Advertising revenue supports our not-for-profit mission.
Check out these best-sellers and special offers on books and newsletters from Mayo Clinic Press.
The challenge ends 10/10. Your gift today can have 5X the impact on AI research and technology.